Seropeutics Information

Seropeutics is an early-stage pharmaceutical company that is advancing breakthrough therapies to treat the orphan indication Fragile X syndrome. We are positioned to deliver two first-in-class drug candidates for clinical development within 12 months of program funding. The lead from our first platform, SERx - 519, is directed at the core Fragile X symptoms that occur in most patients (repetitive behaviors, social deficits, anxiety, cognitive dysfunction); and our second platform candidate, SERx - 480, is focused on the other symptoms that appear frequently in Fragile X syndrome (attention deficit, hyperactivity, psychosis/mania). Both platforms target brain serotonin receptors, an area of intense research over the last two decades. Currently, 18 serotonin receptors are known, several of which have been the targets of commercially successful therapies. What distinguishes Seropeutics is the identification of two distinct, first-in-class chemotypes that selectively modulate novel combinations of serotonin receptors. The unique serotonin receptor activities we have achieved offers the potential to bring efficacious treatments forward for Fragile X syndrome, while dramatically reducing risk of side effects. Seropeutics intends on filing separate INDs for both candidates in 2017 and will seek orphan status for both programs.